LeMaitre Vascular, Inc. (NASDAQ:LMAT) Chairman George W. Lemaitre sold 21,300 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $32.90, for a total value of $700,770.00. Following the sale, the chairman now directly owns 3,405,508 shares of the company’s stock, valued at $112,041,213.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) opened at 32.99 on Friday. The firm has a market cap of $627.54 million, a PE ratio of 47.13 and a beta of 0.65. The firm’s 50-day moving average price is $31.03 and its 200 day moving average price is $27.38. LeMaitre Vascular, Inc. has a 52-week low of $16.80 and a 52-week high of $36.09.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 earnings per share. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd will be issued a dividend of $0.055 per share. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.67%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.88%.
LeMaitre Vascular announced that its board has authorized a share buyback plan on Thursday, July 27th that allows the company to buyback $7.50 million in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 1.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.
WARNING: This piece of content was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/08/13/lemaitre-vascular-inc-nasdaqlmat-chairman-george-w-lemaitre-sells-21300-shares.html.
Several analysts have commented on the company. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research note on Tuesday, August 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price objective (up from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. Benchmark Co. raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 28th. BidaskClub downgraded LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Canaccord Genuity downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price objective for the company. in a research note on Monday, July 10th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $30.17.
Several large investors have recently added to or reduced their stakes in the stock. Bahl & Gaynor Inc. boosted its stake in LeMaitre Vascular by 12.3% in the first quarter. Bahl & Gaynor Inc. now owns 48,585 shares of the medical instruments supplier’s stock worth $1,197,000 after buying an additional 5,320 shares during the period. Ameriprise Financial Inc. boosted its stake in LeMaitre Vascular by 52.3% in the first quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock worth $4,963,000 after buying an additional 69,186 shares during the period. Bank of New York Mellon Corp boosted its stake in LeMaitre Vascular by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock worth $2,181,000 after buying an additional 1,408 shares during the period. American Century Companies Inc. boosted its stake in LeMaitre Vascular by 27.7% in the first quarter. American Century Companies Inc. now owns 192,732 shares of the medical instruments supplier’s stock worth $4,747,000 after buying an additional 41,848 shares during the period. Finally, Algert Global LLC boosted its stake in LeMaitre Vascular by 93.9% in the first quarter. Algert Global LLC now owns 62,062 shares of the medical instruments supplier’s stock worth $1,529,000 after buying an additional 30,062 shares during the period. 67.10% of the stock is currently owned by institutional investors.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.